Document is current
Any future updates will be listed below
-
Authors
Hartl, Lukas
Tatscher, Elisabeth
Weiss, Melanie
Balcar, Lorenz
Strassl, Robert
Jachs, Mathias
Mandorfer, Mattias
Soliman, Thomas
Stadlbauer, Vanessa
Schemmer, Peter
Berlakovich, Gabriela
Tilg, Herbert
Schneeberger, Stefan
Trauner, Michael
Fickert, Peter
Reiberger, Thomas https://orcid.org/0000-0002-4590-3583
Graziadei, Ivo
-
Funding
Funding for this research was provided by:
Medical Scientific Fund of the Mayor of the City of Vienna (MA 40-GMWF-485569-2020)
Medical University of Vienna
- License Information
-
More Information
Article History
Received: 24 August 2022
Accepted: 1 October 2022
First Online: 11 November 2022
Conflict of interest
: M. Mandorfer served as a speaker and/or consultant and/or advisory board member for AbbVie, Collective Acumen, Gilead and W. L. Gore & Associates and received travel support from AbbVie and Gilead. M. Trauner received grant support from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda and Ultragenyx, honoraria for consulting from Albireo, Boehringer Ingelheim, BiomX, Falk, Genfit, Gilead, Intercept, MSD, Novartis, Phenex, Regulus and Shire, speaker fees from Bristol-Myers Squibb, Falk, Gilead, Intercept and MSD, as well as travel support from AbbVie, Falk, Gilead and Intercept and is the co-inventor of patents on the medical use of 24-norursodesoxycholic acid. T. Reiberger received grant support from AbbVie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from AbbVie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from AbbVie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche. L. Hartl, E. Tatscher, M. Weiss, L. Balcar, R. Strassl,M. Jachs, T. Soliman, V. Stadlbauer, P. Schemmer, G. Berlakovich, H. Tilg, S. Schneeberger, , P. Fickert and I. Graziadei declare that they have no competing interests.
